	US 11,857,603 B2
	PTH compounds with low peak-to-trough ratios
Kennett Sprogøe, Holte (DK); Lars Holten-Andersen, Vanløse (DK); David Brian Karpf, Mountain View, CA (US); Felix Cleemann, Mainz (DE); Guillaume Maitro, Mannheim (DE); Mathias Krusch, Hirschhorn (DE); Thomas Wegge, Heidelberg (DE); and Joachim Zettler, Heidelberg (DE)
Assigned to ASCENDIS PHARMA BONE DISEASES A/S, Hellerup (DK)
Filed by ASCENDIS PHARMA BONE DISEASES A/S, Hellerup (DK)
Filed on Nov. 8, 2022, as Appl. No. 18/053,701.
Application 18/053,701 is a continuation of application No. 16/337,955, previously published as PCT/EP2017/074594, filed on Sep. 28, 2017.
Claims priority of application No. 16191454 (EP), filed on Sep. 29, 2016; and application No. 17155846 (EP), filed on Feb. 13, 2017.
Prior Publication US 2023/0218722 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/29 (2006.01); A61K 47/60 (2017.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01)

CPC A61K 38/29 (2013.01) [A61K 9/00 (2013.01); A61K 47/34 (2013.01); A61K 47/60 (2017.08)]

12 Claims

1. A method of treating a human patient having hypoparathyroidism comprising subcutaneously administering to the subject a PTH compound, wherein the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one administration interval at a steady state,

wherein the PTH compound is a water-soluble controlled-release PTH compound of formula (Ia) or a pharmaceutically acceptable salt thereof:

wherein

-D is a PTH moiety, which has the sequence of SEQ ID NO: 51;

-L²-L¹- has the formula:

wherein the unmarked dashed line indicates the attachment to a nitrogen of -D by an amide bond; and the dashed line marked with an asterisk indicates attachment to —Z;

x is 1;

—Z comprises a moiety of formula (b):

wherein the dashed line indicates attachment to -L²and m and p are independently of each other an integer ranging from 150-1000; and

the PTH moiety is released with a release half-life of at least 12 hours.